“Fickleness” in Biological Systems - Really?

University of Arkansas for Medical Science, Little Rock, Arkansas, USA

Corresponding Author:

E. Robert Burns
Director, Department of Neurobiology & Developmental Sciences
UAMS Partners in Health Sciences Program (outreach to PreK-14 teachers) College of Medicine
Slot 510, 4301 West Markham St., Little Rock, Arkansas, USA
Tel: +501-686-5139
E-mail: burnsbob@uams.edu

Received Date: March 11, 2017; Accepted Date: March 14, 2017; Published Date: March 16, 2017

Citation: Burns ER (2017) “Fickleness” in Biological Systems - Really? Arch Sci 1:104.

Copyright: © 2017 Burns ER. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Archives of Science

Commentary

In several news articles in SCIENCE [1] authors reported on the responses of many scientists regarding the irreproducibility of studies in biomedical research, especially cancer biology. The common concerns were “problematic reagents and the fickleness of biological systems”. NATURE continued capturing data on the problem of nonreproducibility, noting that the biomedical science has more nonreproducibility problems than physics, chemistry, and mathematics [2].

Biological variability or “fickleness” is considered by many to be an inherent property that is uncontrollable. This, therefore, leads to major difficulty in reproducing experimental results in the biomedical sciences.

Much of the variability (fickleness) found in research on biological systems, is easy to control if one appreciates the statistically significant fluctuations in all biological variables that occur naturally and reproducibly every day. Without controlling for these normal, significant oscillations, different results will be obtained by different groups of researchers. For example, studying the effect of isoproterenol (IPR) on the rate of DNA synthesis in different mouse organs involved repeating the same experiment at different circadian times, such as every 4 hours (same for the saline treated controls) in different groups of mice [3]. In other words the only variable changing was body clock time. Three different statistically significant conclusions were obtained: IPR stimulated, had no effect or inhibited the rate of DNA synthesis. Which of these results were correct? Actually of them, they just vary depending on the point in the host’s circadian clock system when the intervention occurred. Without an experimental design that controls for circadian variation, the effects of IPR would be irreproducible. Completely different results are a common finding in chronobiological investigations when control treated mice are matched in circadian time to the interventional group and multiple circadian time points are included in the experimental design.

SCIENCE listed research on the biological clock in its top ten list of discoveries of major importance in 1997 [4] and again in 1998 [5], when clock research was first runner-up. This official recognition of the importance of biological rhythmicity 20 years ago apparently has not been heeded by the majority of basic and clinical researcher, leading to non-reproducibility of experimental findings published by different research groups.

There are a variety of pitfalls that researchers fail to control for in biological research on systems that normally and naturally undergo significant oscillation or rhythmicity [6]. In other words, without knowledge of biological rhythmicity as a characteristic of all living things, and not controlling for this natural, statistically significant variability, and the effect this has on experimental design, data acquisition and interpretation, reproducibility is impossible.

With respect to “The Cancer Test” and the problem of nonreproducibility in such an important arena, enough basic animal research in chronobiology, chronotoxicology, chronopharmacology and chronochemotherapy of cancer [7-11], that several successful clinical trials of chronochemotherapy in the human cancer patient have been, as predicted by earlier work with mice, very successful [12-14]. These findings would be reproducible if the dimension of time was appreciated and incorporated in these investigations.

References

1. Kaiser J (2015) The cancer test. Science 348: 1411-1413.
2. Baker M (2016) 1,500 scientists lift the lid on reproducibility. Nature 533: 454.
3. Burns ER, Scheving LE, Tsai TH (1972) Circadian rhythm in uptake of tritiated thymidine by kidney, parotid, and duodenum of isoproterenol-treated mice. Science 175: 71-73.
4. Science (1997) Breakthrough of the year - runners up. 278: 2039.
5. Science (1998) Breakthrough of the year - runners up. 282: 2157.
6. Burns ER (2000) Biological time and in vivo research: a field guide to pitfalls. Anat Rec 261: 141-152.
7. Haus E, Halberg F, Scheving LE, Pauly JE, Cardoso S (1972) Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system. Science 177: 80-82.
8. Garaulet M, Madrid JA (2010) Chronobiological aspects of nutrition, metabolic syndrome and obesity. Adv Drug Delivery Rev 62: 967.
9. Takeda N, Maemura K (2010) Cardiovascular disease, chronopharmacotherapy, and the molecular clock. Adv. Drug Delivery Rev 62: 956.
10. Burioka N, Fukuoka Y, Koyanagi S, Miyata M, Takata M, et al. (2010) Asthma: Chronopharmacotherapy and the molecular clock. Adv Drug Delivery Rev 62: 946.
11. Selfridge JM, Gotoh T, Schiffhauer S, Liu J, Stauffer PE, et al. (2016) Chronotherapy: intuitive, sound, founded…but not broadly applied. Drugs 76: 1507-1521.
12. Hrushesky WJM (1985) Circadian timing of cancer chemotherapy. Science 228: 73.
13. Levi F (2001) Circadian chronotherapy for human cancers. The Lancet Onc 2: 307.
14. Innominato PF, Lévi FA, Bjarnason GA (2010) Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Delivery Rev 62: 979-1001.